Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EVOLOCUMAB Cause Intentional product misuse? 847 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 847 reports of Intentional product misuse have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.6% of all adverse event reports for EVOLOCUMAB.

847
Reports of Intentional product misuse with EVOLOCUMAB
0.6%
of all EVOLOCUMAB reports
1
Deaths
17
Hospitalizations

How Dangerous Is Intentional product misuse From EVOLOCUMAB?

Of the 847 reports, 1 (0.1%) resulted in death, 17 (2.0%) required hospitalization, and 1 (0.1%) were considered life-threatening.

Is Intentional product misuse Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 847 reports have been filed with the FAERS database.

What Other Side Effects Does EVOLOCUMAB Cause?

Device difficult to use (31,807) Drug dose omission by device (23,957) Wrong technique in product usage process (21,664) Accidental exposure to product (16,160) Injection site pain (9,988) Product storage error (6,606) Back pain (5,254) Myalgia (5,061) Drug dose omission (4,914) Injection site bruising (4,409)

What Other Drugs Cause Intentional product misuse?

ETANERCEPT (3,992) PREGABALIN (3,731) BUDESONIDE\FORMOTEROL (3,399) ACETAMINOPHEN (2,924) ESOMEPRAZOLE (2,852) MINOXIDIL (2,418) TOFACITINIB (2,331) CINACALCET (2,092) QUETIAPINE (1,855) ALPRAZOLAM (1,709)

Which EVOLOCUMAB Alternatives Have Lower Intentional product misuse Risk?

EVOLOCUMAB vs EXELON EVOLOCUMAB vs EXEMESTANE EVOLOCUMAB vs EXENATIDE EVOLOCUMAB vs EXFORGE EVOLOCUMAB vs EXJADE

Related Pages

EVOLOCUMAB Full Profile All Intentional product misuse Reports All Drugs Causing Intentional product misuse EVOLOCUMAB Demographics